Microvillus inclusion disease (MYO5B) OMIM 251850
In Microvillus inclusion disease (MYO5B, OMIM 251850), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: — Honest hold (no matched agent). Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5532, γ 1.4875, spinodal 0.6983). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Microvillus inclusion disease is an R19 double-well emerged from the real proximal-promoter DNA of MYO5B. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
- emergent axis
- ↓ DOWN [F]
- healthy branch
- ON
- lesion
- LOF_null
- γ (stiffness)
- 1.4875
- barrier
- 0.5532
- spinodal
- 0.6983
- s_on / s_off
- 1.2196 / -1.2196
- fragility
- 0.21
- corrective polarity
- supply
- forced direction
- raise s toward ON branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5532 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Agents mapped onto the lever
| agent (class) | dir. | status | phase | map |
|---|---|---|---|---|
| apical-membrane-trafficking functional supply (no approved disease-modifying agent; management is parenteral nutrition, supportive) Muller 2008 Nat Genet 40:1163 (MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity) | increase | research | 0 | ◇ in trials |
Evidence & provenance
| element | grade | basis |
|---|---|---|
| R19 switch & cusp geometry (this page) | [V] verified | emerged from measured promoter γ of MYO5B; deterministic, 2×sha256 identical |
| corrective direction | [F] forced | forced by the cusp sign; falsifiable (see lever falsifiers) |
| mapped agents / leads | [O] open | direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude |
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).